Simran Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Simran Kaur has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ayman A. Saleh
Department of Pathology, College of Medicine, University of Ha’il, Hail 55476, Saudi Arabia
1 shared publication - Mai Ali Abdelfattah Ahmed
Department of Pediatrics, College of Medicine, University of Ha’il, Hail 55476, Saudi Arabia
1 shared publication - Mohammad Zeeshan Najm
School of Biosciences, Apeejay Stya University, Sohna, Gurugram 122103, Haryana, India
1 shared publication - Mohd Adnan Kausar
Department of Biochemistry, College of Medicine, University of Ha’il, Hail, Saudi Arabia
1 shared publication - Naveed Iqbal
Department of Obstetrics and Gynecology, College of Medicine, University of Ha’il, Ha’il, Kingdom of Saudi Arabia
1 shared publication - Sadaf Anwar
Department of Biochemistry, College of Medicine, University of Ha’il, Hail, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 2 February 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 215
Autophagy and Cancer: Insights into Molecular Mechanisms and Therapeutic Approaches for Chronic Myeloid Leukemia
Autophagy is a critical cellular process that maintains homeostasis by recycling damaged or aberrant components. This process is orchestrated by a network of proteins that form autophagosomes, which engulf and degrade intracellular material. In cancer, autophagy plays a dual role: it suppresses tumor initiation in the early stages but supports tumor growth and survival in advanced stages. Chronic myeloid leukemia (CML), a hematological malignancy, is characterized by the Philadelphia chromosome, a chromosomal abnormality resulting from a translocation between chromosomes 9 and 22. Autophagy has emerged as a key factor in CML pathogenesis, promoting cancer cell survival and contributing to resistance against tyrosine kinase inhibitors (TKIs), the primary treatment for CML. Targeting autophagic pathways is being actively explored as a therapeutic approach to overcome drug resistance and enhance cancer cell death. Recent research highlights the intricate interplay between autophagy and CML progression, underscoring its role in disease biology and treatment outcomes. This review aims to provide a comprehensive analysis of the molecular and cellular mechanisms underlying CML, with a focus on the therapeutic potential of targeting autophagy.
- 2 February 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (2) , 215
Open AccessAutophagy and Cancer: Insights into Molecular Mechanisms and Therapeutic Approaches for Chronic Myeloid Leukemia
Autophagy is a critical cellular process that maintains homeostasis by recycling damaged or aberrant components. This process is orchestrated by a network of proteins that form autophagosomes, which engulf and degrade intracellular material. In cancer, autophagy plays a dual role: it suppresses tumor initiation in the early stages but supports tumor growth and survival in advanced stages. Chronic myeloid leukemia (CML), a hematological malignancy, is characterized by the Philadelphia chromosome, a chromosomal abnormality resulting from a translocation between chromosomes 9 and 22. Autophagy has emerged as a key factor in CML pathogenesis, promoting cancer cell survival and contributing to resistance against tyrosine kinase inhibitors (TKIs), the primary treatment for CML. Targeting autophagic pathways is being actively explored as a therapeutic approach to overcome drug resistance and enhance cancer cell death. Recent research highlights the intricate interplay between autophagy and CML progression, underscoring its role in disease biology and treatment outcomes. This review aims to provide a comprehensive analysis of the molecular and cellular mechanisms underlying CML, with a focus on the therapeutic potential of targeting autophagy.